An open-label clinical trial reported durable clinical and renal remission in a patient with severe relapsed and refractory lupus nephritis after treatment with allogeneic CD19-targeted CAR-NK cells. The case highlights CAR-NK’s potential to modulate B-cell-driven pathology while avoiding some constraints seen in autologous cell strategies. The most industry-relevant aspect of the item is durability—remission extending beyond the initial response window—along with renal outcomes. Lupus nephritis is a high unmet-need setting where new mechanisms are closely watched for both efficacy and tolerability. For developers, the case supports further cohort expansion and prompts attention to safety surveillance, dose selection and response biomarkers. Because the provided summary is based on a single-trial patient report, it functions as proof-of-concept rather than a definitive efficacy estimate.